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Inotropic support in ischemic acute heart failure is controversial. We tested a therapeutic 25 
principle for acute heart failure by combining a low dose of omecamtiv mecarbil (OM; 0.25 26 
mg/kg bolus plus 0.25 mg/kg/h) with a low dose of dobutamine (Dobut; 1.25 µg/kg/min). In 10 27 
pigs subjected to myocardial ischemia by left coronary microembolization, this cotreatment 28 
increased cardiac power (CP) from 0.48  0.14 to 0.81  0.22 W (p < 0.05). When the drugs 29 
were given as a monotherapy, CP increased from 0.57  0.11 to 0.65  0.15 W (OM; n=5; not 30 
significant) and from 0.40  0.07 to 0.70  0.10 W (Dobut; n=5; p < 0.05). Dobut counteracted 31 
OM-mediated impairments in early relaxation and diastolic shortening. In a second protocol 32 
using the same doses, we assessed cardiac efficiency in five healthy pigs by relating myocardial 33 
oxygen consumption (MVO2) to the pressure-volume area. Here, the increases in cardiac work 34 
and MVO2 were matched, leaving cardiac efficiency unaltered by this drug combination. Low-35 
dose cotreatment with OM+Dobut produces an appropriate hemodynamic effect with improved 36 
CP at doses that do not affect cardiac efficiency. This outcome is mainly attributed to the 37 
inotropic effect of dobutamine. 38 
 39 









The use of inotropic support in ischemic acute heart failure (AHF) is controversial. The ESC  48 
guidelines give the weakest recommendation (class IIb) at the lowest level of evidence (C) for  49 
such treatment1. The reluctance stems from the well-known arrhythmogenic effects2, increased  50 
myocardial energy demands3 and elevated mortality seen in clinical trials following inotrope  51 
therapy4. The adverse events are particularly prominent at a high dosage, which is often  52 
necessary to reach desired treatment goals. AHF patients typically have a previous history of  53 
cardiovascular disease (CVD), with impaired sensitivity in the adrenergic pathway5 and/or are on  54 
oral beta blockers at hospital admission1. These challenges have led to R&D for new inotropes  55 
that do not act on the adrenergic cAMP-mediated pathway. A leading drug in this pipeline is the  56 
myosin activator omecamtiv mecarbil (OM), which is currently under investigation in a phase III  57 
trial, GALACTIC-HF6. OM prolongs the systolic ejection time7, which shortens diastole8. This 58 
finding has raised concerns related to ventricular filling8 and myocardial blood flow9 that are 59 
supported by elevated troponins in clinical trials10,11. Additionally, continuous activation of  60 
myosin ATPase by OM7 causes substantial myocardial oxygen wastage when OM is given as a  61 
monotherapy for experimental AHF12. 62 
 We aimed to assess the therapeutic efficacy of a low-dose cotreatment with omecamtiv  63 
mecarbil and dobutamine (OM+Dobut) in a pig model of ischemic AHF. We hypothesize that  64 
the drugs potentiate systolic unloading and limit the adverse events observed with both drugs at  65 
high dosages. Outcome was assessed by surrogate endpoints such as systolic unloading, diastolic  66 






Experimental animals 72 
All experiments were conducted in accordance to the Consensus Author Guidelines for Animal 73 
Use developed by The International Association of Veterinary Editors (IAVE). A total of 15 74 
castrated male domestic pigs (Sus scrofa domesticus) weighing 25.7  2.0 kg (mean  SD) were 75 
employed. The animals were held in an approved animal facility as previously described8.  76 
 77 
General instrumentation 78 
Induction of anesthesia, intubation and general instrumentation for all animals is described 79 
elsewhere8. 80 
 81 
Closed-chest model of ischemic acute heart failure 82 
Coronary microembolization is a reliable and clinically relevant method to induce ischemic 83 
ventricular dysfunction13. In the present study we used a protocol as previously described14. 84 
Throughout the experiments, continuous infusion of 0.9% NaCl (10 ml/kg/h) was administered 85 
to maintain the circulating volume. Glucose (1.25 g/l) was added to the infusion to maintain 86 
blood glucose levels. After general instrumentation, a Swan-Ganz catheter was placed in the 87 
pulmonary trunk for assessment of central venous and pulmonary arterial pressure, as well as 88 
cardiac output (CO) by thermodilution. Right femoral artery was cannulated to enable 89 
catheterization of left coronary artery main trunk and the following coronary microembolization 90 
protocol. Transthoracic short-axis echocardiography (Vivid I, GE, USA) was used for 91 
calculations of left ventricular (LV) volumes. 92 
5 
Open-chest model for the assessment of cardiac energetics 93 
The open-chest model is previously described in our group15. Healthy pigs were employed to 94 
assess cardiac energetics. Due to increased fluid loss in this open-chest model, a higher NaCl 95 
0.9% volume was infused (20 ml/kg/h). Glucose (1.25 g/l) was added to the infusion to maintain 96 
blood glucose levels. After general surgical preparation, we advanced with 1) median 97 
sternotomy, 2) pericardial removal, 3) hemiazygos vein ligation, 4) dissection to free the 98 
pulmonary trunk, 5) dissection to free the coronary arteries, 6) suture of three sonomicrometric 99 
crystals (Sonometrics Corporation, Canada) into the myocardium, and 7) great cardiac vein 100 
catheterization via the superior vena cava using a pediatric central venous catheter (Arrow 24G; 101 
eSutures, USA). Thereafter, flow probes (Medistim, Norway) were placed around the main 102 
pulmonary- and coronary arteries (right branch, circumflex and left anterior descending) for 103 
measurements of CO and coronary blood flow, respectively. The sonomicrometric crystal 104 
dimensions (apex to basoseptal and basolateral to basoseptal) were calibrated to endocardial LV 105 
dimensions from epicardial echocardiography (Vivid I, GE, USA). 106 
 107 
Experimental protocol 108 
After surgical preparation and stabilization in the closed-chest protocol (n=10), baseline 109 
recordings were performed before LV ischemia by coronary microembolization was induced as 110 
described previously8. Level of ischemic acute heart failure was aimed at reduction in the stroke 111 
volume by approximately 30% and the pulmonary capillary wedge pressure rise to 15-20 mmHg. 112 
An average of 16.1 ± 6.3 ml of microspheres was injected to reach this level of heart failure. 113 
Second recordings were performed approximately 30 minutes after the last injection under stable 114 
hemodynamics. The animals were then randomly divided into two groups to receive either Dobut 115 
6 
(1.25 µg/kg/min) (n=5) or OM (0.25 mg/kg bolus plus 0.25 mg/kg/h) (n=5) as the first treatment. 116 
Monotherapy recordings were performed 30 minutes after the start of drug infusion. The second 117 
drug was added for combination therapy, and final recordings were carried out after 30 minutes 118 
of infusion. 119 
A group of healthy animals (n=5) was employed for the assessment of cardiac energetics. 120 
We performed an open-chest surgical preparation as described above before baseline recordings. 121 
Dobut (1.25 µg/kg/min) was infused for 30 minutes before new recordings, and OM (0.25 mg/kg 122 
bolus plus 0.25 mg/kg/h) in combination with Dobut was infused before the next recordings. 123 
Dobut was then withdrawn before final measurements after 30 minutes of OM  124 
infusion alone. Finally, the left ventricle was weighed after euthanasia by intravenous  125 
pentobarbital sodium injection. Euthanasia was performed according to the regulations on the  126 
use of animals in experiments (Norwegian legislations). 127 
 128 
Left ventricular energetics 129 
Cardiac efficiency was assessed by relating left ventricular work (pressure-volume area, PVA) to  130 
MVO2 at multiple workloads. Multiple workloads were achieved by a stepwise reduction in 131 
preload by inflating a balloon catheter situated in the vena cava as previously described12.  132 
Calculation of PVA and MVO2 is described in detail elsewhere3,12. 133 
 134 
Hemodynamics 135 
Methods for pressure, flow and CO measurements are described earlier by our research group8.  136 
All LV volumes were calculated using the bullet formula16, where 137 
Volume = 5/6 x Area x Length. 138 
7 
End-diastolic and end-systolic areas were measured with short-axis transthoracic  139 
echocardiography, and the long-axis diameter (length) was calculated as 1.37 times the short-axis  140 
diameter obtained by echocardiography17. 141 
 For the closed-chest model, values from transthoracic echocardiography were used to 142 
calculate the volumes. For the open-chest model, endocardial end-diastolic diameters were 143 
obtained at steady-state hemodynamics before preload reductions using epicardial 144 
echocardiography for the calibration of the sonomicrometric crystal-derived short-axis 145 
dimension. Dimensions from crystal signals were used for volume estimations with the same 146 
formula (bullet) at each preload. Hemodynamic data was recorded and analyzed using ADI 147 
labchart software (ADI, New Zealand). 148 
 149 
Statistical analysis 150 
Power analysis (G*Power) was carried out, and results from previous studies were considered to  151 
estimate the number of animals needed. Calculations and statistical analyses after the  152 
experimental protocols were performed using a spreadsheet (Microsoft Excel, Microsoft, USA)  153 
and a statistical package (GraphPad Prism 7, GraphPad, USA). Values are presented as the mean  154 
 standard deviation (Figures 2-4). Repeated measure one-way ANOVA followed by Tukey’s  155 
test for multiple comparisons was used on bar graphs in Figures 3 and 4. Analyses of covariance  156 
(ANCOVA) were used on cardiac energetics data (linear regression Figure 4). P-values < 0.05  157 





Inducing myocardial ischemia by coronary microembolization substantially impaired systolic 162 
function as seen by a halving of end-systolic elastance and preload recruitable stroke work 163 
(Figure 3 G and H). This led to ventricular dilatation (Figure 3 B), rightward shift of the 164 
pressure-volume relationship (Figure 2) and reduced cardiac output (Figure 3 D). Monotherapy 165 
with OM did not restore systolic function in the ischemic hearts (Figures 2 and 3 B-H). However, 166 
its impact on the heart was recognized by characteristic prolongations of systolic ejection time 167 
and impaired early relaxation (SET and Tau; Figure 3 E and F). Low-dose Dobut as 168 
monotherapy did restore systolic function as seen by a normalization of the pressure-volume 169 
relationship (Figure 2 and 3 B), and that cardiac output increased to preischemic levels (Figure 3 170 
D). Also, Dobut restored early relaxation as seen by a normalization of Tau (Figure 3 F).  171 
The relationship between total left ventricular work and MVO2 was measured in five 172 
non-ischemic pigs. As seen from the overlapping confidence interval, none of the drug protocols 173 
had impact on this relationship over a broad range of cardiac workload (Figure 4 left panels). 174 
This suggests that cardiac efficiency was maintained during all treatments and not depending on 175 
workload. At steady-state workload (Figure 4 right panels) both MVO2 and cardiac output 176 





Effect of the drugs on the ischemic heart 182 
The OM dose selected in the present study is comparable to that used in the ATOMIC-HF trial11  183 
for the treatment of AHF. Although this phase II trial did not reach its primary endpoints, i.e.  184 
9 
dyspnea relief, the treatment did improve cardiac function by moderately decreasing LV systolic  185 
dimensions. Such systolic unloading was not seen in the present study using pigs subjected to 186 
ischemic acute heart failure. This discrepancy could not be explained by different sensitivity to 187 
OM between humans and pigs since the functional signature of the drug (prolongation of SET) 188 
was comparable. More likely, the further impairment of diastolic function in the ischemic 189 
ventricle by OM counteracted any systolic improvement in the present study. In contrast, low-190 
dose Dobut monotherapy did, to a large extent, restore cardiac function back to preischemic 191 
levels. This is in line with others giving dobutamine to dogs also subjected to coronary 192 
microembolization13. When the drugs were combined, minimal additive effects were observed 193 
compared to administration of Dobut alone. However, the combination was well tolerated, and 194 
this dual treatment restored cardiac power (CP) to preischemic levels (Figure 3 C). This is 195 
clinically important because CP is the superior early survival predictor in patients hospitalized 196 
with cardiogenic shock18, and in vivo animal experiments can help guide further clinical and pre-197 
clinical studies. Of interest was that Dobut counteracted the unwanted effects of OM on diastole. 198 
This is evident by a normalization of relaxation rate and a relatively prolonged filling time by 199 
shortening the SET. However, a chronotropic effect was seen by this combination treatment that 200 
may be a limitation when treating patients with tachycardia. To our knowledge, this is the first 201 
study to assess this dual inotropic drug target approach for improving systolic function in the 202 
ischemic heart. 203 
 204 
Impact of the drugs on cardiac efficiency 205 
An attempt to use OM as a sole drug in experimental AHF revealed that the drug caused  206 
substantial myocardial oxygen wastage that was suggested to be mediated by hyperactivity in  207 
10 
myosin ATPase12. Such trends were also observed in a study that gave OM to conscious dogs19.  208 
Here, a mismatch of 33% increase in MVO2 versus only a 22% increase in CO was observed  209 
following 24 hours of drug infusion19.  210 
 However, catecholamines also cause myocardial oxygen wastage, particularly prominent  211 
in high doses20. This oxygen wastage is likely mediated by a metabolic switch towards  212 
myocardial fatty acid oxidation21 as well as altered intracellular calcium handling3. However,  213 
during low-dose Dobut infusion, such oxygen waste is not clear20. 214 
 In the present study, we did not observe any significant alteration in cardiac efficiency by  215 
the selected low dose of Dobut, by the low dose of OM, or when the drugs were combined.  216 
When OM and Dobut were combined, the heart responded with a matched increase in MVO2 and  217 
CO. Additionally, when using gold standard methodology (PVA-MVO2 relationship), there was 218 
no indication of surplus MVO2 for any of the interventions. This was seen by that data obtained 219 
during treatment substantially overlapped with baseline recordings over a broad range of cardiac 220 
workloads.  221 
 222 
Effect of the drugs on myocardial perfusion 223 
Concerns have been raised regarding the safety of OM in relation to myocardial perfusion9. The  224 
drug prolongs systole, increases MVO212, and reduces relaxation speed8, which may underlie the  225 
cardiac troponin elevation observed in two clinical trials10,11. Our study did not show any  226 
indication of myocardial malperfusion when OM was combined with Dobut. Blood gas  227 
analysis showed that the oxygen saturation in blood drained from the great cardiac vein was  228 
never below 21%, and myocardial lactate uptake was present at all measurement points (range  229 
11 
0.95 – 1.74 g/min). However, a net global lactate uptake in the myocardium does not exclude 230 
regional lactate release from ischemic regions22. 231 
 232 
Limitations 233 
Our study was carried out in healthy juvenile pigs, which are different from typical AHF patients  234 
with old age and a previous history of CVD. An animal model in which coronary perfusion is  235 
truly challenged, such as coronary stenosis and tachycardia, is warranted to gain the necessary  236 
knowledge on the safety of this cotreatment scheme in ischemic heart disease. Additionally, the  237 
timeframe of this study is shorter than the typical clinical time course of AHF. This precludes the 238 
use of troponin as a quantitative measure of myocardial damage in this study. This is unfortunate 239 
since elevated troponin is observed in clinical trials using omecamtiv. Also, activation of 240 
lipoprotein lipase and the subsequent initiation of fatty acid metabolism by adrenergic 241 
stimulation occurs over time. Thus, a longer study period using this cotreatment protocol for 242 
assessing cardiac efficiency is warranted. 243 
Cardiac energetics was not assessed in a heart failure model like the coronary 244 
microembolization cohort. The rationale to use a separate non-ischemic protocol is, by our 245 
experience, the most sensitive setup to detect any surplus MVO2.  246 
The closed chest AHF cohort aims to reassemble the clinical setting of patients admitted 247 
to the ICU with ischemic acute heart failure. Sternotomy and the following cardiac 248 
instrumentation as required for assessing energetics is a considerable surgical trauma. This 249 
impacts general hemodynamics, thus an induction of severe myocardial ischemia in addition to 250 
this often leads to hemodynamic collapse in the need for inotropes. This would preclude the pre-251 
drug measurements. 252 
12 
Further, ischemia is often complicated with episodes of arrhythmia. This limits the 253 
accuracy of the PVA-MVO2 recordings substantially. Also, the accuracy of the work 254 
independent assessment of energetics by regression analysis is dependent on the range of 255 
workloads. This is carried out in an unloading protocol by restricting venous return. A 256 
compromised circulation (i.e. AHF) does not allow much unloading before organ malperfusion 257 
sets in.  258 
Previously, our group have documented that therapeutic levels of omecamtiv impacts 259 
cardiac efficiency quantitatively similar in both preischemic and ischemia-reperfusion induced 260 
acute heart failure12. Thus, the fact that no impact on cardiac efficiency was seen in an optimized 261 
preischemic model, we see it as highly unlikely that this conclusion would differ in an AHF 262 
model. Finally, this study assessed the therapeutic effects using only single doses. This may 263 




Combination treatment with low-dose omecamtiv mecarbil and dobutamine is well tolerated in 268 
the ischemic heart. This drug combination does not aggravate cardiac efficiency, as it does not 269 
alter the MVO2-work relation. However, the data does not support our hypothesis that this 270 
cotreatment potentiates systolic function, as the restoration of cardiac function is almost 271 
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Figure legends 356 
 357 
Figure 1. 358 
Schematic diagram summarizing the two protocols used. OM, Omecamtiv Mecarbil (0.25 mg/kg 359 
bolus plus 0.25 mg/kg/h); Dobut, dobutamine (1.25 µg/kg/min).  360 
 361 
Figure 2. Pressure-volume relations from ischemic acute heart failure pigs. 362 
Left ventricular (LV) end-systolic and end-diastolic pressure-volume relationships (ESPVR and 363 
EDPVR) in healthy pigs (black) subjected to ischemic acute heart failure by left coronary 364 
microembolization (gray). The left panel shows data from five pigs in which dobutamine (Dobut; 365 
yellow) was given as the first treatment. The middle panel shows five pigs in which omecamtiv 366 
mecarbil (OM; blue) was given first. In both groups, the second inotrope was subsequently added 367 
for the assessment of OM+Dobut cotreatment (green). The right panel shows data for both 368 
groups together with an illustration of LV pressure-volume loops. All data are presented as the 369 
mean ± standard deviation. 370 
 371 
Figure 3. Hemodynamic indices from ischemic acute heart failure pigs. 372 
Following baseline recordings (stripe), the animals were subjected to left ventricular (LV) 373 
ischemia (blank) by coronary microembolization. The pigs received either dobutamine (Dobut; 374 
n=5, gray, left stack) or omecamtiv mecarbil (OM; n=5, gray, right stack) as the first drug. The 375 
second drug was subsequently added for final recordings of the cotreatment (OM+Dobut; black). 376 
16 
HR, heart rate; ESV, end-systolic volume obtained by transthoracic echocardiography of the LV 377 
short axis; CP, cardiac power is cardiac output multiplied by LV developed pressure; CO cardiac 378 
output measured by thermodilution; SET, systolic ejection time is the time between peak positive 379 
and peak negative derivatives of LV pressure (dP/dtmax and dP/dtmin, respectively); Tau, the time 380 
constant of LV isovolumetric relaxation calculated by Weiss’s method; PRSW, preload 381 
recruitable stroke work is the slope of the relation between end-diastolic volume and stroke work 382 
during rapid preload reductions; Ees, end-systolic elastance is the slope of the end-systolic 383 
pressure-volume relation. Bars indicate mean values with standard deviations. Brackets indicate 384 
statistical significance. P-values < 0.05 were considered statistically significant. 385 
 386 
Figure 4. Cardiac energetics in healthy pigs. 387 
Cardiac efficiency data from 5 pigs at baseline (striped bar, solid line), after receiving 388 
dobutamine (Dobut; gray bar, dotted line), after adding omecamtiv mecarbil (OM+Dobut); black 389 
bar, dotted line), and after withdrawal of Dobut (OM; gray bar, dotted line). Left panels show 390 
regression lines including 95% confidence intervals of the relationship between left ventricular 391 
oxygen consumption (MVO2) and total mechanical work (pressure-volume area, PVA) at 392 
multiple workloads. At each timepoint, 7-9 recordings of the PVA-MVO2 relationship were 393 
carried out by a stepwise reduction in preload. None of the regressions were significantly 394 
different. The right panels show steady-state MVO2 and cardiac output measurements from the 395 
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